Severe Clinical Course in a Patient with Congenital Amegakaryocytic Thrombocytopenia Due to a Missense Mutation of the c-MPL Gene

Abstract:
Congenital amegakaryocytic thrombocytopenia (CAMT) generally begins at birth with severe thrombocytopenia and progresses to pancytopenia. It is caused by mutations in the thrombopoietin receptor gene, the myeloproliferative leukemia virus oncogene (c-MPL). The association between CAMT and c-MPL mutation type has been reported in the literature. Patients with CAMT have been categorized according to their clinical symptoms caused by different mutations. Missense mutations of c-MPL have been classified as type II and these patients have delayed onset of bone marrow failure compared to type I patients. Here we present a girl with severe clinical course of CAMT II having a missense mutation in exon 4 of the c-MPL gene who was admitted to our hospital with intracranial hemorrhage during the newborn period.

Key Words: Congenital amegakaryocytic thrombocytopenia, Thrombopoietin, c-MPL, Homozygous missense mutation, c-MPL Tryp154Arg, Amino acid change

Özet:
Konjenital amegakaryositik trombositopeni (KAMT) genellikle, doğumda ağır trombositopeni ile başlar ve pansitopeniye ilerler. Hastalığın nedeni trombopoetin reseptör geni olan myeloproliferatif lösemi virüs onkogenindeki (c-MPL) mutasyon olup, literatürde KAMT kliniği ile c-MPL mutasyon tipleri arasında ilişki bildirilmiş, hastalar farklı mutasyonların neden olduğu klinik belirtilere göre sınıflandırılmışlardır. c-MPL’nin yanlış anlamlı mutasyonları tip 2 olarak sınıflanmıştır. Bu hastalar tip 1 hastalar ile karşılaştırıldığında kemik iliği yetmezliğinin daha geç başladığı bildirilmiştir. Burada, yeniden doneminde intrakranial kanama ile hastanemize başvuran c-MPL geninde ekzon 4’de yanlış anlamlı mutasyonu olan KAMT II tanılı ağır klinik seyirli bir kız sunulmuştur.

Anahtar Sözcükler: Konjenital amegakaryositik trombositopeni, Trombopoetin, Homozigot yanlış anlamlı mutasyon, c-MPL Tryp154Arg, Amino asit değişikliği
Introduction

Congenital amegakaryocytic thrombocytopenia (CAMT), one of the autosomal recessive hereditary bone marrow deficiency syndromes, generally begins at birth with severe thrombocytopenia and progresses to pancytopenia [1]. Other syndromes presenting with severe thrombocytopenia at birth are thrombocytopenia with the absence of the radius bone, amegakaryocytic thrombocytopenia with radioulnar synostosis, and Paris-Trousseau syndrome. The molecular pathophysiology of CAMT was explained after the discovery of thrombopoietin (TPO) and its receptor, namely the myeloproliferative leukemia virus oncogene (c-MPL) [2]. The c-MPL gene consists of 12 exons located in the 1p34 locus. In the literature, 41 mutations in the c-MPL gene were defined [1,3,4]. Most CAMT patients have homozygous or compound heterozygous mutations in the c-MPL gene, which lead to absent or impaired reactivity to TPO [5]. Ballmaier et al. published a series of CAMT cases in 2001 and suggested 2 groups of genotype-phenotype features. CAMT I is a severe course of the disease with early development of pancytopenia due to a complete loss of function of the TPO receptor. However, CAMT II patients may show a transient increase of platelet counts during the first year of life with missense mutations of the c-MPL gene [2]. Clinical highlights of CAMT are severe thrombocytopenia secondary to ineffective thrombopoiesis and bone marrow deficiency due to a failure of early hematopoietic progenitors. This indicates the critical role of TPO in both megakaryocytosis and maintenance of stem cells [4]. Thrombocytopenia or associated symptoms appear in 70% of cases at birth and 90% of cases in the first year of life [1].

We hereby present a girl with a severe clinical course of CAMT II having a missense mutation in exon 4 of the c-MPL gene who was admitted to our hospital with intracranial hemorrhage (ICH) during the newborn period. Informed consent was obtained.

Case Presentation

A 2-day-old girl was admitted to our hospital with petechiae and purpura. Her past medical history revealed that she had ICH at the 28th week of gestation as detected by fetal ultrasonography. No fetal intervention was applied. She was born by cesarean section at the 38th week of gestation with a birth weight of 2750 g. Her parents were first cousins. On physical examination, no congenital abnormalities were revealed. Cranial USG revealed ICH and head computed tomography showed a severe parenchymal hemorrhage on her first day of life. Initial laboratory studies revealed hemoglobin (Hb) of 134 g/L, white blood cell (WBC) count of 10.3x10^9/L, platelet (PLT) count of 6x10^9/L, and mean platelet volume of 6 fL. Her mother’s platelet count was normal. Bone marrow aspiration disclosed absence of megakaryocytes. She was diagnosed with CAMT. Analysis of the patient’s TPO revealed a very high level (564 pg/mL; normal range: 120±76 pg/mL); however, her parents’ TPO levels were below 32 pg/mL. Molecular analysis disclosed a homozygous missense mutation in exon 4, which causes a change in arginine instead of tryptophan at the 154th amino acid position. The same heterozygote mutation was detected in her mother, father, and 2 siblings. However, she was lost to follow-up for 2 years. Two years later, she was admitted to our intensive care unit with gastrointestinal bleeding. At that time, laboratory analysis revealed Hb of 47 g/L, WBC count of 8.2x10^9/L, absolute neutrophil count of 3.7x10^9/L, and PLT count of 5x10^9/L. Her bone marrow aspiration smears revealed a decline in bone marrow cellularity and erythroid and myeloid cells, in addition to a decreased number of megakaryocytes (Figure 1). Bone marrow biopsy showed 25% cellularity and a few megakaryocytes were confirmed by CD61 staining. During the follow-up period, an intraventricular shunt was placed in order to treat increased intracranial pressure due to ICH in the prenatal period. During her follow-up for the last 2 years, she has had pancytopenia. The search for a bone marrow donor was unsuccessful among both family and unrelated donors.

Discussion and Review of the Literature

CAMT is a rare disorder characterized by the lack of megakaryocytic progenitors in the bone marrow. Patients with CAMT are categorized according to their clinical symptoms caused by different mutations [6]. The first group, CAMT I, has total loss of TPO receptors due to homozygous nonsense mutations, deletions, and frame shift mutations, and its clinical course is more severe than that of the other

Figure 1. Progression of bone marrow failure in a child with CAMT. A, B, C- Bone marrow aspiration performed at 2 years of age showed no megakaryocytes in a cellular particle with erythroid and myeloid precursors without dysplasia (100X, 1000X, 1000X, respectively). D, E, F- Bone marrow aspirate showed very hypocellular results with few lymphocytes at 2.5 years of age (100X, 100X, 1000X, respectively).
In conclusion, CAMT is a rare cause of thrombocytopenia in childhood. Children suspected of CAMT should be analyzed for mutations in *c-MPL*, confirmative for the diagnosis of CAMT. The role of the clinical phenotypes of CAMT I and CAMT II is not yet clear, especially regarding the development of bone marrow failure and the influence of other regulatory genes and epigenetic factors on the phenotype of CAMT.

Acknowledgment

We thank Dr. M. Germeshausen, Hannover Medical School, Germany, for analysis of the TPO levels and genetic mutations in our patient and her family members.

Conflict of Interest Statement

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

1. Ballmaier M, Germeshausen M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Semin Thromb Hemost 2011;37:673-681.
2. Ballmaier M, Germeshausen M, Schulze H, Cherkouki K, Lang S, Gaudig A, Krukemeier S, Eilers M, Strauss G, Welte K. *c-mpl* mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001;97:139-146.
3. Savoia A, Dufour C, Locatelli F, Noris P, Ambaglio C, Rosti V, Zecca M, Ferrari S, di Bari F, Corcione A, Di Stazio M, Seri M, Baldini CL. Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica 2007;92:1186-1193.
4. Geddis AE. Congenital amegakaryocytic thrombocytopenia. Pediatr Blood Cancer 2011;57:199-203.
5. Ballmaier M, Germeshausen M. Advances in the understanding of congenital amegakaryocytic thrombocytopenia. Br J Haematol 2009;146:3-16.
6. Geddis AE. Inherited thrombocytopenias: an approach to diagnosis and management. Int J Lab Hematol 2013;35:14-25.
7. Germeshausen M, Ballmaier M, Welte K. *MPL* mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Hum Mutat 2006;27:296.
8. King S, Germeshausen M, Strauss G, Welte K, Ballmaier M. Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br J Haematol 2005;131:636-644.
9. Stoddart MT, Connor P, Germeshausen M, Ballmaier M, Steward CG. Congenital amegakaryocytic thrombocytopenia (CAMT) presenting as severe pancytopenia in the first month of life. Pediatr Blood Cancer 2013;60:E94-E96.
10. Nagata Y, Shozaki Y, Nagahisa H, Nagasawa T, Abe T, Todokoro K. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost 1997;77:808-814.
11. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (*c-Mpl* ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720-2730.
12. Mukai HY, Kojima H, Todokoro K, Tahara T, Kato T, Hasegawa Y, Kobayashi T, Ninomiya H, Nagasawa T, Abe T. Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. Thromb Haemost 1996;76:675-678.